All these treatments are performed outside Spain, in Eastern European countries, within the European Union, and/or in Middle Eastern countries, where there is NO prohibition as in Spain for the application of these treatments.
We advise all cancer patients to read this IMPORTANT book about the reality of cancer. CANCER: THE SURPRISING TRUTH. Its author is the prestigious molecular biologist Travis Christofferson. We recommend it for all cancer patients and of course for all physicians and oncologists.
IMMUNOTHERAPY WITH CIK CELL VACCINE
Cancer immunotherapy with cytokine-induced killer cells (CIKs) is one of the treatments for passive immunotherapy because, unlike active immunotherapy with dendritic cell preparations, CIKs are able to bind directly to and kill cancer cells. Numerous clinical trials have shown that CIK cells can help prevent disease recurrence, stop its progression, and increase overall survival, while improving the quality of life of cancer patients. The main active cells in CIK are CD3+ / CD56+ cells, which are rarely found in uncultured peripheral blood. They have high proliferation rates and potent anti-cancer effects due to the dual functional action of T cells and NK cells, are low in cytotoxicity to healthy cells, but have a particularly specific effect on cancer cells.
Once in the patient's body, the CIK immediately travels to the site where the tumor forms and begins to kill the cancer cells. They detect the latter in response to alarms sent by the patient's body. CIKs work instantly, they don’t need any help from the patient’s own immune system. This is especially important in patients whose condition is so weak that the body is no longer able to respond to the disease on its own. Due to this property, CIKs are classified as passive immunotherapy because they do not strengthen the human immune system, but fundamentally change it.
Passive immunotherapy methods, such as CIK or monoclonal antibodies, are also perfectly compatible with active immunotherapy, which aims to mobilize the patient's immune system. This combination makes it possible to exploit both the speed of passive therapy and the long-term effectiveness of active therapy. An excellent example of a combination of these methods could be treatment with both CIK and dentritic cells. These therapies work on very different principles, but at the same time create a broad and complex response to cancer. There is evidence that chemotherapy increases the sensitivity of cancer to immunotherapy and radiation therapy, and vice versa. Based on these data, the concept of chemoimmunotherapy is gaining ground in oncology, which states that immunotherapy, chemotherapy, or target therapy alone are not capable of effectively controlling cancer, and therefore a rational combination of these cancer treatments is necessary.
Request information without obligation
Request information without obligation, we will study your case with our medical team to give you an answer as soon as possible.